Results of the dermatitis clinical trial scheduled for this summer :: InvestMacro

Enrollment is now in phase 2a of the VYNE Therapeutics Inc. trial. Encouraged by the Phase 1B efficacy data, as noted by the HC Wainwright & Co.

VYNE Therapeutics Inc. (VYNE: NASDAQ) Finished enrolling patients, on schedule, in the Phase 2A trial evaluating FMX114 in mild to moderate atopic dermatitis, and results are expected in late July and early August of this year, according to Joseph Pantgenis, an analyst at HC Wainwright & Co at Search June 17 Note.

It should also be noted that HC Wainwright’s target price on VYNE of $7 per share indicates a significant potential return for investors given the biopharmaceutical company’s current share price is approximately $0.50.

In a Phase 2A, double-blind study, 25 enrolled patients will receive FMX114 and vehicle treatment four times daily for four weeks, relaying Pantginis. The objective is to further evaluate the safety, pharmacokinetics, and efficacy of the company’s proprietary combination of tofacitinib and fingolimod.

Pantginis highlighted that the results for part 1b of stage 1b/2a are encouraging. Patients showed a significant reduction in the signs and symptoms of atopic dermatitis after 2 weeks of FMX114 treatment. The treatment is also proven to be safe.

In the report, Pantginis also provided updates on two immune-modified VYNE assets, VYN201 and VYN202. These are the BET inhibitors derived from the InhiBET platform.

Get our free MetaTrader 4 indicators – Put our free MetaTrader 4 custom indicators on your charts when you join our weekly newsletter

Get weekly commitment to merchant reports Find out where the largest traders (hedge funds and commercial hedgers) are located in the futures markets on a weekly basis.

“BET proteins are key regulators of inflammation and tumorigenesis through transcriptional modulating mechanisms,” the analyst explained.

As for VYN201, a locally administered pan-bromodomain inhibitor, it “has shown strong preclinical efficacy on a number of indicators of inflammation,” Pantginis noted. Newly released data on VYN201 show that it safely provides immunosuppression.

VYNE intends to pursue VYN201 in the case of vitiligo first, due to market potential, “impressive raw data” and a significant unmet need, Pantginis wrote. “Current treatments for vitiligo are limited in their ability to generate a rapid response, are usually stressful for patients, and have limited durability.”

As such, the company is targeting H2/22 to launch a Phase 1a/b clinical trial for VYN201 vitiligo.

“This is an important step forward for VYNE and its InhiBET platform, and we look forward to updates in the coming months,” Pantgenis added.

For the later phase of VYNE, orally administered VYN202, biologics have not yet decided which systemic indication to follow first, but options include rheumatoid arthritis, systemic lupus erythematosus, ulcerative colitis/Crohn’s disease, and multiple sclerosis. VYNE is looking forward to beginning, later this year, a Phase 1 trial of VYN202 in the signal of your choice.

HC Wainwright & Co. acquired. A buy rating on VYNE.


1) Doresa Banning wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or her family members own the securities of the following companies mentioned in the article: None. She or her family members get paid by the following companies mentioned in this article: None.

2) The following companies mentioned in this article are sponsors of Streetwise Reports billboards: None. click over here For important disclosures about sponsor fees.

3) Comments and opinions expressed are those of specific experts and are not those of Streetwise Reports or its officials. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.

4) The material does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional, and any action the reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ full legal terms of use disclaimer. This article is not a solicitation to invest. Streetwise Reports does not provide general or specific investment advice, and the information in Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the businesses, products, services, or securities of any company mentioned in Streetwise Reports.

5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the Site, may have a long or short position in said securities. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or selling such securities on the open market or otherwise from the time of the decision to publish an article until three business days after the article was published. The foregoing prohibition does not apply to articles that merely repeat in substance the company’s previously published versions. –

6) This article does not constitute medical advice. The officers, employees, and contributors of Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

HCWainwright & Co. Disclosures , VYNE Therapeutics, Inc. June 17, 2022

HC Wainwright & Co, LLC (the “Company”) is a member of FINRA, SIPC, and a US registered broker-dealer.

I’m Joseph Pantgenis, Ph.D. and Emanuela Branchte, Ph.D. certify that 1) all opinions expressed in this report accurately reflect my personal opinions about any and all subject securities or issuers discussed; and 2) no part of my salary was, or would be, directly or indirectly related to the specific recommendation or opinions expressed in this research report; 3) Neither I nor any of my family members is an official, director, or member of the advisory board of these companies.

Neither the research analyst nor the research analyst family has a financial interest in the securities of VYNE Therapeutics, Inc. (including, without limitation, any option, right, security, future position, long or short). As of May 31, 2022, neither the Company nor its affiliates beneficially owns 1% or more of any class of common stock of VYNE Therapeutics, Inc.. Neither the Research Analyst nor the Company knows or has reason to know any other material conflict of interest in At the time of publication of this research report.

The research analyst primarily responsible for preparing the report does not receive compensation based on any specific investment banking services or transactions, but is compensated based on factors including total revenue and the company’s profitability, a large part of which is derived from investment banking services. The Company or its affiliates have received compensation from VYNE Therapeutics, Inc. For non-investment banking services in the past 12 months. Neither the Company nor its affiliates have received any compensation from VYNE Therapeutics, Inc. for investment banking within twelve months prior to that, but will seek compensation from the companies mentioned in this report for investment banking within three months after publication of the research report. The company does not create a marketplace in VYNE Therapeutics, Inc. As of the date of this research report.

The securities of the company discussed in this report may not be suitable for investors depending on their specific investment objectives and financial situation. Past performance is not a guarantee of future results. This report is provided for informational purposes only, and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such is prohibited. This research report is not intended to provide tax advice or be used to provide tax advice to anyone. Electronic versions of HC Wainwright & Co., LLC’s research reports are made available to all customers simultaneously. No part of this report may be reproduced in any form without the express permission of HC Wainwright & Co., LLC. Additional information is available upon request.

HC Wainwright & Co., LLC does not provide individually tailored investment advice in research reports. This research report is not intended to provide personal investment advice and does not take into account the specific investment objectives, financial situation and special needs of any particular person. Investors should seek financial advice regarding the appropriateness of investing in financial instruments and implementing the investment strategies discussed or recommended in this research report. Sales representatives, dealers, and other professionals of HC Wainwright & Co. may provide

HC Wainwright & Co., LLC and its affiliates and their officers, directors and employees, excluding its analysts, will from time to time have long or short positions in the securities or derivatives (including options and warrants) of the covered companies referenced in this research report.

The information here is based on sources we believe to be reliable but we do not guarantee it to be accurate nor purport to be a complete statement or summary of the available data about the company, industry, or security discussed in the report. All opinions and estimates contained in this report constitute the judgment of the analyst as of the date of this report and are subject to change without notice. Securities and other financial instruments discussed in this research report: may lose value; Not insured by the Federal Deposit Insurance Corporation; They are subject to investment risks, including potential loss of the principal amount invested.

Source link

Add a Comment

Your email address will not be published.